TransEnterix Announces Dismissal of Federal Securities Class Action
09 Octubre 2017 - 5:55AM
Business Wire
TransEnterix, Inc. (NYSE American: TRXC), a medical device
company that is pioneering the use of robotics to improve minimally
invasive surgery, today announced that the United States District
Court for the Eastern District of North Carolina dismissed the
securities class action suit filed in June 2016.
On October 6, 2017, the U.S. District Court for the Eastern
District of North Carolina entered final judgment in favor of
TransEnterix, Inc. and all other defendants dismissing the putative
securities class action complaint against them. The dismissal
followed the Court's ruling that the plaintiffs' allegations lacked
merit and failed to state a viable claim.
“We are pleased that the securities class action suit was
dismissed,” said Todd M. Pope, President and CEO at TransEnterix.
“We remain confident in achieving FDA 510(k) clearance of the
Senhance Surgical Robotic System and continue to focus on
transitioning toward U.S. commercialization.”
About TransEnterix
TransEnterix is a medical device company that is pioneering the
use of robotics to improve minimally invasive surgery by addressing
the clinical and economic challenges associated with current
laparoscopic and robotic options. The company is focused on the
commercialization of the Senhance Surgical Robotic System, a
multi-port robotic system that brings the advantages of robotic
surgery to patients while enabling surgeons with innovative
technology such as haptic feedback and eye sensing camera control.
The company is also developing the SurgiBot™ System, a single-port,
robotically enhanced laparoscopic surgical platform. The Senhance
Surgical Robotic System has been granted a CE Mark, and is
currently under FDA review for clearance in the United States. For
more information, visit the TransEnterix website at
www.transenterix.com.
Forward Looking Statements
This press release includes statements relating to the Senhance™
Surgical Robotic System and our current regulatory and
commercialization plans for this product. These statements and
other statements regarding our future plans and goals constitute
"forward looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control and which may cause results to differ materially from
expectations and include whether the Senhance Surgical Robot will
be approved by the FDA in 2017. For a discussion of the risks and
uncertainties associated with TransEnterix's business, please
review our filings with the Securities and Exchange Commission
(SEC), including our Annual Report on Form 10-K filed on March 7,
2017 and our other filings we make with the SEC. You are cautioned
not to place undue reliance on these forward looking statements,
which are based on our expectations as of the date of this press
release and speak only as of the origination date of this press
release. We undertake no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171009005329/en/
For TransEnterix, Inc.Investor Contact:Mark Klausner, +1
443-213-0501invest@transenterix.comorMedia Contact:Mohan
Nathan, +1 919-765-8400media@transenterix.com
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024